Zydus Reports Positive Phase II(b) Results for Saroglitazar Mg in MASH
Zydus Lifesciences has announced positive topline results from its global EVIDENCES-X™ Phase II(b) clinical trial evaluating Saroglitazar Magnesium in patients with Metabolic dysfunction-Associated Steatohepatitis (MASH) and fibrosis. The company said the study successfully achieved its primary endpoint, marking an important milestone in its ongoing MASH development programme.






















